Vonetize Plc: Update regarding the sale of the controlling shareholders’ shares to US based Desilu Studios Inc.; target price unchanged at NIS 1.43

• jaimeuss_admin
• 17 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Brainsway Ltd: The company’s main competitor has completed an IPO, providing for a new benchmark to Brainsway’s valuation; target price unchanged.

• jaimeuss_admin
• 17 בSeptember 2018
• Research
• 0 Comments

Continue Reading

RedHill Biopharma announces positive top-line results from Phase III study of RHB-104 in Crohn’s Disease; remission rates at week-52 are low by market comparison; Redhill plans to raise additional capital to support future clinical development; target price remains at NIS 2.59

• jaimeuss_admin
• 16 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed Pharmaceuticals Inc.: Sufficient funds for clinical development activity over the next 24 months; several clinical milestones are scheduled for 2018 and 2019; as Oramed’s clinical progress meets our expectations, stock target price remains at NIS 53.2.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Enlight Renewable Energy Ltd: Significant regualtory progress brings Enlight closer to final-stage approvals for the Bereshit wind farm; stock target price unchanged.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Entera Bio Ltd., a subsidiary of DNA Biomedical Solutions Ltd. has announced the share pricing for its forthcoming IPO (Nasdaq); As pricing was at similar valuation to our initiation report, target price remains unchanged.

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading